Format

Send to

Choose Destination
Breast Cancer Res. 2019 Mar 21;21(1):43. doi: 10.1186/s13058-019-1127-y.

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

Author information

1
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia.
2
Systems Biology Ireland, University College Dublin, Belfield, Dublin 4, Ireland.
3
St Vincent's Hospital Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.
4
School of Medicine, University of Notre Dame, Sydney, NSW, 2011, Australia.
5
School of Medical Sciences, University of New South Wales, Sydney, NSW, 2025, Australia.
6
Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland.
7
School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland.
8
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia. d.croucher@garvan.org.au.
9
St Vincent's Hospital Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia. d.croucher@garvan.org.au.
10
School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland. d.croucher@garvan.org.au.

Abstract

BACKGROUND:

The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplified breast cancer patients for two decades. However, the lack of response and the rapid onset of relapse in many patients now question the assumption that the ERBB2/ERBB3 heterodimer is the sole relevant effector target of these therapies.

METHODS:

Through a systematic protein-protein interaction screen, we have identified and validated alternative RTKs that interact with ERBB2. Using quantitative readouts of signalling pathway activation and cell proliferation, we have examined their influence upon the mechanism of trastuzumab- and pertuzumab-mediated inhibition of cell growth in ERBB2-amplified breast cancer cell lines and a patient-derived xenograft model.

RESULTS:

We now demonstrate that inactivation of ERBB3/PI3K by these therapeutic antibodies is insufficient to inhibit the growth of ERBB2-amplified breast cancer cells. Instead, we show extensive promiscuity between ERBB2 and an array of RTKs from outside of the EGFR family. Paradoxically, pertuzumab also acts as an artificial ligand to promote ERBB2 activation and ERK signalling, through allosteric activation by a subset of these non-canonical RTKs. However, this unexpected activation mechanism also increases the sensitivity of the receptor network to the ERBB2 kinase inhibitor lapatinib, which in combination with pertuzumab, displays a synergistic effect in single-agent resistant cell lines and PDX models.

CONCLUSIONS:

The interaction of ERBB2 with a number of non-canonical RTKs activates a compensatory signalling response following treatment with pertuzumab, although a counter-intuitive combination of ERBB2 antibody therapy and a kinase inhibitor can overcome this innate therapeutic resistance.

KEYWORDS:

Breast cancer; ERBB2; Heterodimers; Pertuzumab; Receptor tyrosine kinases

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center